England M R, Gordon G, Salem M, Chernow B
Department of Anesthesia, New England Medical Center Hospital, Tufts University School of Medicine, Boston, Mass.
JAMA. 1992 Nov 4;268(17):2395-402.
To determine whether magnesium administration is effective in reducing postoperative morbidity and mortality after cardiac surgery.
Randomized, double-blind, placebo-controlled trial.
A tertiary acute-care 500-bed university teaching hospital.
Over a 6-month period, 100 patients electively scheduled for cardiac surgery involving cardiopulmonary bypass were studied.
Fifty patients were randomized to receive an intravenous infusion of magnesium chloride, 2 g, and 50 patients received placebo intraoperatively after the termination of cardiopulmonary bypass.
Magnesium-treated patients had a significantly decreased frequency (P < .04) of postoperative ventricular dysrhythmias (eight [16%] of 50) compared with placebo-treated patients (17 [34%] of 50). Patients who were normomagnesemic postoperatively had new supraventricular dysrhythmias less frequently (P < .03) than patients who were hypomagnesemic postoperatively (eight [17%] of 48 vs 19 [37%] of 52). Compared with placebo-treated patients, magnesium-treated patients had significantly higher (P < .02) postoperative cardiac indices in the intensive care unit (2.8 +/- 0.1 vs 2.5 +/- 0.1 L/min per m2). Patients with postoperative total and ultrafilterable hypomagnesemia had postoperative ventricular dysrhythmias (P < .04) and required prolonged mechanical ventilatory support (P < .01) more frequently than patients without postoperative hypomagnesemia.
Total and ultrafilterable hypomagnesemia are prevalent findings in cardiac surgery patients, and postoperative hypomagnesemia is strongly associated with clinically important morbidity. Magnesium administration decreased the frequency of postoperative ventricular dysrhythmias and increased the stroke volume and thereby cardiac index in the early postoperative period.
确定给予镁剂是否能有效降低心脏手术后的发病率和死亡率。
随机、双盲、安慰剂对照试验。
一家拥有500张床位的三级急症大学教学医院。
在6个月的时间里,对100例择期进行涉及体外循环的心脏手术的患者进行了研究。
50例患者被随机分配接受静脉输注2克氯化镁,50例患者在体外循环结束后术中接受安慰剂。
与接受安慰剂治疗的患者(50例中的17例[34%])相比,接受镁治疗的患者术后室性心律失常的发生率显著降低(P <.04)(50例中的8例[16%])。术后血镁正常的患者新发室上性心律失常的频率低于术后血镁过低的患者(P <.03)(48例中的8例[17%] 对比52例中的19例[37%])。与接受安慰剂治疗的患者相比,接受镁治疗的患者在重症监护病房的术后心脏指数显著更高(P <.02)(2.8 +/- 0.1对比2.5 +/- 0.1 L/分钟每平方米)。与无术后低镁血症的患者相比,术后出现总镁和超滤性低镁血症的患者术后室性心律失常(P <.04)和需要延长机械通气支持的频率更高(P <.01)。
总镁和超滤性低镁血症在心脏手术患者中很常见,术后低镁血症与具有临床重要性的发病率密切相关。给予镁剂可降低术后室性心律失常的发生率,并增加心输出量,从而提高术后早期的心脏指数。